Skip to main content


Medically reviewed by Last updated on Jul 9, 2020.


(ROE moe SOZ ue mab)

Index Terms

  • Romosozumab-aqqg

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Prefilled Syringe, Subcutaneous [preservative free]:

Evenity: Romosozumab-aqqg 105 mg per 1.17 mL (1.17 mL)

Brand Names: U.S.

  • Evenity

Pharmacologic Category

  • Monoclonal Antibody
  • Sclerostin Inhibitor


Romosozumab inhibits sclerostin, a regulatory factor in bone metabolism that inhibits Wnt/Beta-catenin signaling pathway regulating bone growth (MacDonald 2009; McClung 2018); romosozumab increases bone formation and to a lesser extent, decreases bone resorption.


Vdss: ~3.92 L


Has not been characterized; expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG

Onset of Action

Peak increase in bone formation marker procollagen type 1 N-telopeptide (P1NP) and peak decrease in bone resorption marker type 1 collagen C-telopeptide (CTX) observed 2 weeks after initiation. Increased histomorphometric indices of bone formation observed 2 months after therapy initiation.

Time to Peak

Median: 5 days (range: 2 to 7 days)

Duration of Action

CTX decrease persists throughout 12 months of therapy; P1NP returns to baseline by 9 months and declines at 12 months; anabolic effect wanes after 12 months of treatment. After discontinuation of therapy, an increase in CTX above baseline value occurs within 3 months. CTX, P1NP, and bone mineral density (BMD) return to baseline within ~12 months of discontinuing therapy.

Half-Life Elimination

12.8 days after 3 doses over 12-week period (ie, 1 dose every 4 weeks)

Special Populations Note

Weight: The exposure of romosozumab decreases with increasing body weight.

Use: Labeled Indications

Osteoporosis: Treatment of osteoporosis in postmenopausal females at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.

Limitations of use: The anabolic effect of romosozumab wanes after 12 monthly doses of therapy. Therefore, the duration of romosozumab use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered.


Hypersensitivity (eg, angioedema, erythema multiforme, urticaria) to romosozumab or any component of the formulation; uncorrected hypocalcemia

Dosing: Adult

Note: Correct hypocalcemia prior to initiation of therapy. Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.

Osteoporosis, treatment (postmenopausal females):

Note: Use may be considered for reduction of vertebral (and possibly hip and nonvertebral) fractures in patients with very high fracture risk, including those with a T-score less than –3, a T-score less than –2.5 with fracture history, multiple prior vertebral fractures, a fracture within prior 12 months, or a very high fracture risk according to a risk assessment tool; may also be used as an alternative agent in patients for whom first-line therapies are not tolerated or are ineffective. Women at high risk of cardiovascular disease and stroke (eg, prior history of myocardial infarction or stroke) should not be considered for treatment (AACE/ACE [Camacho 2020]; ES [Shoback 2020]).

SubQ: Two consecutive injections (105 mg each) for a total dose of 210 mg once monthly.

Discontinuation/interruption of therapy: Because the benefits of anabolic therapy are quickly lost after discontinuation (eg, within 12 months), it is generally recommended to initiate antiresorptive therapy (eg, bisphosphonate or denosumab) to maintain bone mineral density gains following a course of romosozumab (AACE/ACE [Camacho 2020]; Cosman 2016; ES [Shoback 2020]; Saag 2017; manufacturer’s labeling).

Duration of therapy: 12 months.

Missed dose: If a dose is missed, administer as soon as it can be rescheduled; subsequent doses should be scheduled every month from the date of last dose.

Dosing: Geriatric

Refer to adult dosing.


SubQ: Each monthly dose consists of 2 consecutive SubQ injections.

Remove 2 syringes from carton and allow to sit at room temperature for at least 30 minutes before administration. Administer into the abdomen, thigh, or outer area of upper arm; should only be administered by a health care professional. Rotate injection sites; if the same injection site is chosen, do not inject into the same spot used for the first injection. Avoid areas of skin that are tender, bruised, red, hard, scarred, or with stretch marks. Solution in syringe should appear clear to opalescent, colorless to light yellow; do not use if cloudy, discolored, or contains particulate matter.

Dietary Considerations

Osteoporosis prevention or treatment: Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Females and males should consume:

Calcium: 1,000 mg/day (males: 50 to 70 years of age) or 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).

Vitamin D: 800 to 1,000 units daily (males and females ≥50 years of age) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 units daily (males and females ≤70 years of age) or 800 units daily (males and females ≥71 years of age) (IOM 2011).


Refrigerate at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake. Upon removal from the refrigerator, may store at room temperature up to 25°C (77°F) in the original carton for up to 30 days. If not used within 30 days, discard. Do not expose to temperatures >25°C (77°F).

Drug Interactions

There are no known significant interactions.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Neuromuscular & skeletal: Arthralgia (8% to 13%)

1% to 10%:

Cardiovascular: Cardiac disorder (2%), peripheral edema (2%)

Central nervous system: Headache (5% to 7%), insomnia (2%), paresthesia (1%)

Dermatologic: Skin rash (1%)

Hypersensitivity: Hypersensitivity reaction (7%)

Local: Injection site reaction (5%), pain at injection site (2%), erythema at injection site (1%)

Neuromuscular & skeletal: Muscle spasm (3% to 5%), asthenia (3%), neck pain (2%)

<1%, postmarketing, and/or case reports: Acute myocardial infarction, angioedema, cerebrovascular accident, dermatitis, erythema multiforme, femur fracture, hypocalcemia, osteonecrosis of the jaw, urticaria

ALERT: U.S. Boxed Warning

Potential risk of myocardial infarction, stroke and cardiovascular death

Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, romosozumab should be discontinued.


Concerns related to adverse effects:

• Bone fractures: Atypical femur fractures have been reported in patients receiving romosozumab. The fractures may occur anywhere along the femoral shaft (may be bilateral) and commonly occur with minimal to no trauma to the area. Some patients experience prodromal pain weeks or months before the fracture occurs. New or unusual thigh, hip, or groin pain should be reported to health care provider; any patient with thigh or groin pain should be suspected of having an atypical femur fracture and should be evaluated to rule out an incomplete femur fracture. If an atypical fracture is present, assess for signs/symptoms of fracture in contralateral limb. Consider interruption of therapy based on benefits/risks.

• Cardiovascular events: [US Boxed Warning]: Romosozumab may increase the risk of MI, stroke, and cardiovascular death and should not be initiated in patients who have had an MI or stroke within the previous year. Consider benefits/risks of therapy in patients with other cardiovascular risk factors. Discontinue use if MI or stroke occurs during therapy.

• Hypocalcemia: Hypocalcemia may occur. Correct hypocalcemia prior to initiation of therapy (contraindicated in patients with uncorrected hypocalcemia). Ensure adequate supplementation with calcium and vitamin D during therapy and monitor calcium levels closely, particularly in patients predisposed to hypocalcemia (eg, severe renal impairment and/or receiving dialysis).

• Hypersensitivity: Hypersensitivity reactions (eg, angioedema, erythema multiforme, urticaria, rash, dermatitis) have occurred; discontinue use for serious reactions (eg, anaphylaxis) and treat appropriately.

• Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving romosozumab. Known risk factors for MRONJ include tooth extraction or other invasive dental procedures, cancer diagnosis, radiotherapy, concomitant therapy (eg, angiogenesis inhibitors, bisphosphonates, chemotherapy, corticosteroids, denosumab), poor oral hygiene, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Routine oral exam is recommended prior to initiation of therapy; patients should maintain good oral hygiene during treatment. Consider risk/benefits of therapy in patients requiring invasive dental procedures. Patients developing ONJ during therapy should receive care by an oral surgeon or dentist; consider discontinuation of therapy based on risk/benefit assessment.

Monitoring Parameters

Signs/symptoms of hypersensitivity; signs/symptoms of adverse cardiovascular events; serum calcium.

Bone mineral density (clinical trials assessed at baseline and then at 6 or 12 months [Cosman 2016; Saag 2017]); may consider monitoring biochemical markers of bone turnover (eg, fasting serum CTX, serum P1NP) at baseline, 3 months, and 6 months to assess treatment response (Cosman 2016; ES [Eastell 2019]; Saag 2017).

Reproductive Considerations

Romosozumab is not indicated for use in females of reproductive potential.

Pregnancy Considerations

Romosozumab is a humanized monoclonal antibody (IgG2). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).

Romosozumab is not indicated for use in females of reproductive potential.

Patient Education

What is this drug used for?

• It is used to treat soft, brittle bones (osteoporosis) in women who have been through menopause (change of life).

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Joint pain

• Headache

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Heart attack like chest pain; pain in arms, back, neck, jaw, or abdomen; shortness of breath; cold sweats; severe dizziness; passing out; or severe nausea or vomiting.

• Weakness on 1 side of the body, trouble speaking or thinking, change in balance, drooping on one side of the face, or blurred eyesight

• Low calcium like muscle cramps or spasms, numbness and tingling, or seizures.

• Groin, hip, or thigh pain

• Jaw swelling

• Jaw pain

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.